PepGen Inc. (PEPG)
PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.
PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-TermAYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm